Shares of Senti Biosciences slid 10.4% to $0.40 on August 14 after the gene-circuit cell therapy company posted second-quarter results that were worse than expected on nearly every measure, while warning it may not have enough money to keep the lights on past the end of 2026. Senti Biosciences Is Running Out of Cash and Time — Is Celadon's Lifeline Enough to Keep the Lights On?
Shares of Senti Biosciences sank 10.4% to $0.40 after the clinical-stage biotech disclosed a second-quarter net loss of $12.75 million and adjusted earnings per share of -$0.42, badly missing the -$0.26 Wall Street estimate. Cash on hand shrank to just $6.5 million by June 30, and management warned funding may not stretch past the fourth quarter — a flashing red signal that the company could run dry within months.
The Cash Pile Is Vanishing at an Alarming Rate. A year ago, Senti held roughly $21.6 million in cash; by year-end 2024 that figure was $48.3 million after fundraising. By March 31, 2026, just $8.9 million remained after $7.5 million in quarterly operating cash burn. Now at $6.5 million, the trajectory is clear: without new money, operations halt. For shareholders, this means further dilution — issuing new shares to raise capital — is virtually guaranteed, shrinking the value of each existing share.
Management's Own Filing Confirms Survival Is in Doubt. Management explicitly states "substantial doubt about continuing as a going concern." That phrase — an auditor's way of saying a company may not survive as an ongoing business — forces institutional investors and funds with risk mandates to reconsider their positions. It also weakens Senti's hand in any negotiation with partners or lenders.
A $40 Million Convertible Note Deal Comes With Steep Strings Attached. Celadon Partners agreed to provide up to $40 million in senior secured convertible notes — $10 million initially, with $30 million at the investor's discretion.
The notes must be repaid at 200% of principal at maturity if not converted to stock , and include full-ratchet anti-dilution protection that concentrates financing risk with a related party.
Celadon already controls 54.6% of Senti's shares. Translation: the biggest shareholder is tightening its grip under terms heavily favoring itself.
The Science May Be Promising, but Markets Don't Fund Hope Indefinitely. The FDA gave positive feedback supporting a pivotal-stage trial for Senti's lead cancer therapy for acute myeloid leukemia. That's a genuine milestone. But with trailing revenue near just $38,000 , Senti is a company that burns millions each quarter while generating almost nothing. At $0.40 a share, the market is pricing in serious doubt that the science will ever reach a patient's bedside.